Bio-Thera Reports the Results for BAT2206 in P-III Trial for the Treatment of Plaque Psoriasis
Shots:
- The P-III clinical trial evaluated the efficacy, safety, immunogenicity & PK of BAT2206 vs Stelara in patients (n=556) with moderate too severe plaque psoriasis
- The results from the study depicted that the 1EP of improvement in PASI score to wk12 with BAT2206 showed similar effects to originator. Results will be soon announced in medical conference
- BAT2206 is a biosimilar version of Stelara (ustekinumab) and is the Bio-Thera's 4th biosimilar to achieve positive P-III results. In Aug 2021, Bio-Thera entered into a commercialization and license agreement with Hikma for BAT2206
Ref: HCP Live | Image: Bio-Thera Solutions
Related News:- Bio-Thera Reported Positive Results of BAT2206 (biosimilar ustekinumab) in P-III Study for Patients with Plaque Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
